Introduction: The aim of the study was to assess the association of elevated serum pregnancy associated plasma protein A (PAPP-A) and the risk of all-cause mortality, cardiovascular events and mortality due to infection in patients with chronic kidney disease (CKD).
Material and methods: We systematically searched the Medline database up to March 2017. A random effects model was used to pool the relative risks (RRs) and their 95% confidence intervals (CIs). Sensitivity analysis and subgroup analysis were performed to explore the potential sources of heterogeneity.
Results: Six studies involving 2034 subjects were included. The pooled RRs for the risk of all-cause mortality and cardiovascular events were 1.50 (95% CI: 1.17-1.92), 1.26 (95% CI: 0.95-1.69), respectively. Sensitivity analysis by excluding each individual study showed no influence on the main results. Subgroup analysis showed that age, male proportion, follow-up term, and assay methods were not modifiable factors.
Conclusions: Our study suggests that elevated serum PAPP-A is associated with the risk of all-cause mortality in patients with CKD.
Keywords: all-cause mortality; chronic kidney disease; meta-analysis; pregnancy-associated plasma protein A.
Copyright: © 2019 Termedia & Banach.
Conflict of interest statement
The authors declare no conflict of interest.
Pregnancy-associated plasma protein A predicts adverse vascular events in patients with coronary heart disease: a systematic review and meta-analysis.Arch Med Sci. 2013 Jun 20;9(3):389-97. doi: 10.5114/aoms.2013.35421. Epub 2013 May 28. Arch Med Sci. 2013. PMID: 23847657 Free PMC article.
Antioxidants for chronic kidney disease.Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076940 Review.
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30132304 Free PMC article.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Cochrane Database Syst Rev. 2014. PMID: 24880031 Review.
Association of Optimism With Cardiovascular Events and All-Cause Mortality: A Systematic Review and Meta-analysis.JAMA Netw Open. 2019 Sep 4;2(9):e1912200. doi: 10.1001/jamanetworkopen.2019.12200. JAMA Netw Open. 2019. PMID: 31560385 Free PMC article.
- Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. - PubMed
- Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–14. - PubMed
- Sud M, Tangri N, Pintilie M, Levey AS, Naimark D. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation. 2014;130:458–65. - PubMed
- Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610–23. - PubMed